MGA Entertainment to make hairless Bratz, Moxie Girlz dolls

The campaign started by non-Hodgkin's lymphoma survivor Jane Bingham to see toy maker Mattel create a bald Barbie to help support kids who have lost their hair due to anti-cancer treatments has succeeded, but not quite in the way she expected.

After months of refusal and admittedly under enormous pressure, Mattel finally conceded to make a bald Barbie, but they would only do so in a limited manner, saying in a statement:

"We made the decision not to sell these dolls at retail stores, but rather get the dolls directly into the hands of children who can most benefit from the unique play experience."

While this is a victory for Bingham, it's not what she was after--which was to see the dolls appear on store shelves. Fortunately, another toy maker has stepped up and promised to have a line of hairless dolls on store shelves this summer.

That toy maker is MGA Entertainment, makers of the Bratz and Moxie Girlz lines of dolls.

Source: NPR

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap